MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3350/cmh.2014.20.4.376

Медицинская библиотека · Clinical and molecular hepatology · 2014

Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.

Kim Jae Hyun, Kim Jung Min, Cho Youn Zoo, Na Ji Hoon, Kim Hyun Sik, Kim Hyoun A, Kang Hye Won, Baik Soon Koo, Kwon Sang Ok, Cha Seung Hwan, Kim Young Ju, Kim Moon Young

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND/AIMS: Angiotensin receptor blockers (ARBs) inhibit activated hepatic stellate cell contraction and are thought to reduce the dynamic portion of intrahepatic resistance. This study compared the effects of combined treatment using the ARB candesartan and propranolol versus propranolol monotherapy on portal pressure in patients with cirrhosis in a prospective, randomized controlled trial.

METHODS

Between January 2008 and July 2009, 53 cirrhotic patients with clinically significant portal hypertension were randomized to receive either candesartan and propranolol combination therapy (26 patients) or propranolol monotherapy (27 patients). Before and 3 months after the administration of the planned medication, the hepatic venous pressure gradient (HVPG) was assessed in both groups. The dose of propranolol was subsequently increased from 20 mg bid until the target heart rate was reached, and the candesartan dose was fixed at 8 mg qd. The primary endpoint was the HVPG response rate; patients with an HVPG reduction of >20% of the baseline value or to <12 mmHg were defined as responders.

RESULTS

The mean portal pressure declined significantly in both groups, from 16 mmHg (range, 12-28 mmHg) to 13.5 mmHg (range, 6-20 mmHg) in the combination group (P<0.05), and from 17 mmHg (range, 12-27 mmHg) to 14 mmHg (range, 7-25 mmHg) in the propranolol monotherapy group (P<0.05). However, the medication-induced pressure reduction did not differ significantly between the two groups [3.5 mmHg (range, -3-11 mmHg) vs. 3 mmHg (range, -8-10 mmHg), P = 0.674]. The response rate (55.6% vs. 61.5%, P = 0.435) and the reductions in mean blood pressure or heart rate also did not differ significantly between the combination and monotherapy groups.

CONCLUSIONS

The addition of candesartan (an ARB) to propranolol confers no benefit relative to classical propranolol monotherapy for the treatment of portal hypertension, and is thus not recommended.

Для цитирования: Kim Jae Hyun, Kim Jung Min, Cho Youn Zoo, Na Ji Hoon, Kim Hyun Sik, Kim Hyoun A, Kang Hye Won, Baik Soon Koo, Kwon Sang Ok, Cha Seung Hwan, Kim Young Ju, Kim Moon Young. Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.. Clinical and molecular hepatology. 2014. DOI: 10.3350/cmh.2014.20.4.376.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.